Paper Details

  1. Home
  2. Paper Details

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Author: BisgaardH, BrattonD L, FranchiL M, KnorrB, LeSouefP, MicheleT M, NguyenH H, ReissT F, SantanelloN, VermeulenJ H

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the efficacy and safety of montelukast, a leukotriene receptor antagonist, in preschool children with persistent asthma. Montelukast was found to be safe and effective in this age group, and it is the first large multicenter study to address the effects of this drug in children younger than 5 years old.
Paper Details　
Original Abstract of the Article :
The greatest prevalence of asthma is in preschool children; however, the clinical utility of asthma therapy for this age group is limited by a narrow therapeutic index, long-term tolerability, and frequency and/or difficulty of administration. Inhaled corticosteroids and inhaled cromolyn are the mos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1542/peds.108.3.e48

データ提供：米国国立医学図書館（NLM）

Montelukast for Persistent Asthma in Young Children

This study examines the efficacy and safety of montelukast, a leukotriene receptor antagonist, in treating persistent asthma in preschool children, a population often facing challenges with traditional asthma medications. The researchers conducted a large, multicenter study evaluating the effects of montelukast on asthma control in children aged 2 to 5 years. The study found that montelukast effectively controlled asthma symptoms in this age group, providing a valuable treatment option for young children with persistent asthma.

Montelukast: A Potential Solution for Young Children with Asthma

This study is like a desert oasis offering relief for young children with asthma. The findings suggest that montelukast, with its convenient once-daily chewable tablet formulation, provides an effective and safe treatment option for this challenging population. This study is a beacon of hope for families seeking effective ways to manage their children’s asthma.

Managing Asthma in Children: A Collaborative Journey

If your child is diagnosed with asthma, it’s essential to work closely with your pediatrician to develop a comprehensive management plan. They can help you understand your child’s individual needs and recommend the most appropriate treatment options. It's important to remember that managing asthma is a collaborative effort, requiring close communication between families and healthcare providers.

Dr.Camel's Conclusion

This study provides valuable insights into the treatment of persistent asthma in young children, offering a promising option for families seeking effective and safe solutions. It’s a reminder that the desert of childhood asthma can be navigated with the right knowledge, support, and treatment options.

Date :
  1. Date Completed 2001-10-18
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

11533366

DOI: Digital Object Identifier

10.1542/peds.108.3.e48

Related Literature

Article Analysis
・Effects of cromolyn oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.